Adaptive Biotechnologies Corp vs General Motors Company — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while General Motors Company trades at $89 (market cap $78.40B). The key difference: General Motors Company is far larger — about 19.4× Adaptive Biotechnologies Corp's market cap, and General Motors Company pays a 0.81% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GM | |
|---|---|---|
Market Cap | $4.04B | $78.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $90.30 |
52-Week Low | $12.30 | $54.16 |
Enterprise Value | $4.10B | $181.38B |
Dividend Yield | — | 0.81% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →